Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.65 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.65 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599554 | 0.87 | PRSS1 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7895751 | 0.85 | ALDH1A1 (0.64) | ALDH1A1HPGDRAB9ACA12CA1 | |
| SCHEMBL13989319 | 0.82 | GAA (0.73) | ALDH1A1HPGDRAB9ACA12CA1 | |
| SCHEMBL13714942 | 0.82 | ITGB3 (0.70) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL13094273 | 0.82 | ITGB3 (0.66) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL13094271 | 0.82 | ITGB3 (0.66) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL841312 | 0.82 | ITGB3 (0.66) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL1438132 | 0.82 | PRSS1 (0.65) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL20012525 | 0.81 | ITGB3 (0.65) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL9517500 | 0.81 | ALDH1A1 (0.68) | ALDH1A1HPGDRAB9ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1810971-B1 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-1606287-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-1819684-B1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INT BV (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2548874-A2 | Substituted piperazines as CB1 antagonists | Intervet International B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-10-17 | — | — | US | disclosed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002058732-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058685-A2 | COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058733-A2 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058696-A2 | THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | PPARG, PPARA, PPARD | F2 739/4885PRSS1 540/4885PRSS2 1350/4885 |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | F2 2267/4885PRSS1 581/4885PRSS2 1038/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | F2 314/4885PRSS1 398/4885PRSS2 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.